empower pharmacy ghk cu Logo Empower Pharmacy Opens $55M Facility
Description
The company told Korea Biomedical Review in a note Friday that it will discontinue the supply of Nexium IV from the first half of 2026, citing a combination of portfolio shifts, local generic competition, and an intent to focus on the next wave of innovative medicines for Korean patients
doi:10.1016/j.jns.2009.04.003 37
Any deviation can dramatically alter its conformational shape, its binding affinity, and ultimately, its observed effects in your research models
New York: Thieme Publishers
